Buradasınız

Anasayfa » Content

FOLLİKÜLER KÖKENLİ TİROİD TÜMÖRLERİNİN TANISINDA HBME-1 ANTİKORUNUN YERİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The value of HBME-1 immunoreactivity in the differential diagnosis of follicular derived thyroid tumors. HBME-1 monocional antibody, initially developed against to mesothelial cells, is also claimed to have immunoreactivity with follicular derived thyroid tumors. In tbis study the utility of HBME-1 antibody in the differential diagnosis of neoplastic and non-neop-lastic lesions of thyroid has been investigated. HBME-1 antibody was applied to 40 cases of thyroid tumours and lesİons.Imrmınohistochemİcal method was used. Ali papiliary carcinomas showed strong and diffuse immunoreactivity (10/10), but only 3 cases of nodular goitres with papiliary hypcıplasİa (3/6) and follicular adenomas (3/5) had heterogeneous positivity. 2 cases of follicular carcinoma (2/3) and 7 cases of poorly differentiated carcinomas (7/12) were found to have İmmunoreactivity for anti-HBME-1 antibody. 2 cases of Graves' diseasc and Hurthle celi carcinomas did not show any immunoreactivity. In conelusion, HBME-I antibody can be used as an adjunct imnıunostain to conventional histopathological criteria to differentiate papiliary carcinomas of the thyroid from benign lesions. We suggest fhat negative immunoreactivity may be used as a firıding supporting the diagnosis of a benign lesion.
Bookmark/Search this post with
Abstract (Original Language): 
Mezotel hücre belirleyicisi olarak geliştirilen HBME-1 monoklonal antikorunun, tiroidin iyi diferansiye folliküler kökenli karsinomiarmda da İmmiinreaktivitc gösterdiği bildirilmektedir. Bu çalışmada HBME-1 antikorunun tiroidin oldukça sık karşılaşılan ncoplastik, non-neoplastık lezyonlanııın ayırımındaki değerinin araştırılması hedeflendi. Bu amaçla, tiroid neoplazisi veya non-neoplastik lezyonu olan toplam 40 vakada HBME-1 immünreaktivitesi araştırıldı. Papiller karsinomlamı tümünde (10/10) kuvvetli ve diffüz immünreaktivite belirlendi. Papillcr hiperplazi içeren nodüllerin (3/6) ve folliküler adcnomlarm üçünde (3/5) heterojen, değişik yoğunluklarda pozitİvİte gözlendi. Folliküler karsinomlarm ikisinde (2/3), az diferansiye karsi-nomlann yedisinde (7/12) immünreaktivite dikkati çekti. Graves hastalığı olan iki vc Hurthle hücreli karsinomu olan iki vakada pozitiviteye rastlanmadı. Bu bulguların ışığında, HBME-1 antikorunun, tiroidin papiller lczyonlannın ayırıcı tanısında klasik histopatolojİk kriterlere yardımcı olarak kullanılabileceği, özellikle immünreaktivitenin belirlenmemesinin, benign lezyon lehine bir bulgu olarak değerlendirilebileceği sonucuna varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-follikuler-kokenli-tiroid-tumorlerinin-tanisinda-hbme-1-antikorunun-yeri.pdf
  • 2
159-163
  • Turkish

REFERENCES

References: 

î. Baltİfora H, McCaısghey WTE: Tumors of the serous menıbranes. "Atlas of the tumor patbology, editör: Rosai J, AFIP, Washington DC, (1995)", p:62.
2. Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martînez-Tello FJ, e! al: Detectİon of high mobility gro-ııp [ HMG1(Y) protein in tfıe diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58: 4193 (1998).
3. GhaÜ VS, Jimenez EJS, Garcia RL: Distribution of leu-7 antigen (HNK-I) in thyroid tumors. It's usefulness as a diagnostic marker lor follicular and papiliary carcinoma. Hum Pathol 23:21 (1992).
4. McLaren KM, Cossar DW: The immıınohistochernical localizalion of S-100 in the diagnosis of papiliary carcinoma of the thyroid. Hum Pathol 27: 633 (1996).
5. Miettinen M, Kovatieh AJ: HBME-1, a monoclonal antibody useful in the differential diagnosis of mesothelio-ma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem 3:115 (1995).
6. Miettinen M, Kârkkâinen P: Differential reaclivity of HBME-1 and CD-15 antibodies in benign and malignant thyroid lumors. Preferential reactivity with maîignant tumors. Vircbows Arch 429:213 (1996).
7. O'Hara BJ, Paetau A, Miettinen M: Kcratin subsets and monoclonal antibody HBME-1 in choıdoma: immuno-histoehemical differential diagnosis between tumors si-mulaüngchordoma. Hum Pathol 29: 119 (1998).
8. Ordonez NG: îhe value of anübodies 44-3A6, SM3, HBME-1, and thronıbomodulin in differentiating epithe-lial pîeural mesothelioma from lung adenocarcinoma: a compaıative study with other commonly used antibodies. Anı J SurgPathoi21: 1399 (1997).
9. Ordonez NG: Role of immnnohistochcmistry in distingu-ishing epitlıcîial peritoneal mesotheliomas from peritone-al and ovarİan serous carcinomas. Am J Surg Pathol 22: 1203 (1998).
10. Sack MJ, Astengo-Osuna C, Y Un BT, Battifora H, Li-volsi VA: HBME-1 immunostaining in thyroid fine-ne-edle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668 (1997).
11. Schelfhout LJDM, van Muijen GNP, Fleuren GJ: Exp-ression of keratin 19 distinguishes papiüary thyroid carcinoma from follicular carcinoma and follicular thyroid adenoraa. Am J Clin Pathol 92:654 (J989).

Thank you for copying data from http://www.arastirmax.com